Lexaria Bioscience Corp.
Lexaria Bioscience Corp. (LEXXW) Stock Overview
Explore Lexaria Bioscience Corp.’s financial performance, market position, analyst ratings, and future outlook.
LEXXW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Lexaria Bioscience Corp. (LEXXW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.81.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.60 and a market capitalization of 17.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Mr. Richard C. Christopher
7
740 McCurdy Road, Kelowna, NV
1970